Issues dealing with newborn screening.
Issues dealing with Alzheimer's treatments.
Issues dealing with the addition of Spinal Muscular Atrophy to the Recommended Uniform Screening Panel.
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Issues dealing with value-based contracts.
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Duration: December 1, 2014
to
December 31, 2018
General Issues: Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Taxation/Internal Revenue Code , Copyright/Patent/Trademark , Health Issues
Spending: about $750,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Charles Brain Asst. to the President, Dp. Chief Staff W&M Cmte.
Asst. to the President, Dp.Chief Staff W&M Cmte
Asst to the President, Dep COS W&M Comm
A. J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
Beau Schuyler LD-Cong. Tanner, LD-Cong. McIntyre, SA-Cong. Rose
LD-CongTanner,LD-CongMcIntyre,SA-CongRose
Leg Dir Rep. Tanner, Leg Dir Rep. McIntyre, SA Rep. Rose
LD.-Cong. Tanner, LD-Cong. McIntyre, SA-Cong Rose
LD-CongTanner,LD-Cong.McIntyre,SA-CongRose
Heather McHugh LD-Sen. Chuck Schumer
Legislative Director, Sen. Chuck Schumer
Leg Dir Sen. Charles Schumer
A.J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2018
Capitol Hill Strategies, LLC terminated an engagement in which they represented Biogen Inc on Jan. 15, 2019.
Original Filing: 301004647.xml
Lobbying Issues
Issues dealing with newborn screening.
Issues dealing with Alzheimer's treatments.
Issues dealing with the addition of Spinal Muscular Atrophy to the Recommended Uniform Screening Panel.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Issues dealing with value-based contracts.
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Capitol Hill Strategies, LLC lobbied for Biogen Inc , earning $40,000. The report was filed on Oct. 18, 2018.
Original Filing: 300989149.xml
Lobbying Issues
Issues dealing with newborn screening.
Issues dealing with Alzheimer's treatments.
Issues dealing with the addition of Spinal Muscular Atrophy to the Recommended Uniform Screening Panel.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Issues dealing with value-based contracts.
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Capitol Hill Strategies, LLC lobbied for Biogen Inc , earning $40,000. The report was filed on July 19, 2018.
Original Filing: 300969764.xml
Lobbying Issues
Issues dealing with newborn screening.
Issues dealing with Alzheimer's treatments.
Issues dealing with the addition of Spinal Muscular Atrophy to the Recommended Uniform Screening Panel.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Children's Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Issues dealing with value-based contracts.
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Capitol Hill Strategies, LLC lobbied for Biogen Inc , earning $40,000. The report was filed on April 13, 2018.
Original Filing: 300944498.xml
Lobbying Issues
Issues dealing with newborn screening.
Issues dealing with Alzheimer's treatments
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Children's Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Issues dealing with value-based contracts.
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Capitol Hill Strategies, LLC lobbied for Biogen Inc , earning $40,000. The report was filed on Jan. 16, 2018.
Original Filing: 300924393.xml
Lobbying Issues
Issues dealing with newborn screening.
Issues dealing with Alzheimer's treatments
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Children's Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018; specifically, changes to the orphan drug tax credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Capitol Hill Strategies, LLC lobbied for Biogen Inc , earning $40,000. The report was filed on Oct. 18, 2017.
Original Filing: 300906480.xml
Lobbying Issues
Issues dealing with newborn screening.
H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Issues dealing with Alzheimer's treatments
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Children's Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive Tax Reform legislation, generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $40,000. The report was filed on July 18, 2017.
Original Filing: 300886992.xml
Lobbying Issues
Issues dealing with newborn screening.
H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Issues dealing with Alzheimer's treatments
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive Tax Reform legislation, generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $40,000. The report was filed on April 20, 2017.
Original Filing: 300872594.xml
Lobbying Issues
Issues dealing with newborn screening.
PDUFA Reauthorization legislation (bill text and number pending), legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive Tax Reform legislation, generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848305.xml
Lobbying Issues
H.R. 34, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Issues dealing with newborn screening.
S. 1878, Advancing Hope Act of 2015 legislation that amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 19, 2016.
Original Filing: 300831664.xml
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Issues dealing with newborn screening.
S. 1878, Advancing Hope Act of 2015 legislation that amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300814958.xml
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Issues dealing with newborn screening.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300798099.xml
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)
S.632, Support Technology and Research for Our Nation's Growth Patents Act of 2015
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 2700, FDA and NIH Workforce Authorities Modernization Act
S. 185, Promise for Antibiotics and Therapeutics for Health Act
S. 2713, Advancing Precision Medicine Act of 2016
S. 2745, Advancing NIH Strategic Planning and Representation in Medical Research Act
S. 2742, Promoting Biomedical Research and Public Health for Patients Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Jan. 18, 2016.
Original Filing: 300774302.xml
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)
S.632, Support Technology and Research for Our Nation's Growth Patents Act of 2015
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300765242.xml
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act
S.632, Support Technology and Research for Our Nation's Growth Patents Act of 2015(BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $50,000. The report was filed on July 15, 2015.
Original Filing: 300734957.xml
Lobbying Issues
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act
S.632, Support Technology and Research for Our Nation's Growth Patents Act of 2015(BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $60,000. The report was filed on April 15, 2015.
Original Filing: 300716116.xml
Lobbying Issues
Draft 21st Century Cures legislation under consideration by the House Energy & Commerce Committee (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies)
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Patent Reform Legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2014
In Q4, Capitol Hill Strategies, LLC lobbied for Biogen Idec , earning $20,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696759.xml
Lobbying Issues
Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2014
Capitol Hill Strategies, LLC filed a lobbying registration on Dec. 16, 2014 to represent Biogen Idec, effective Dec. 1, 2014.
Original Filing: 300692006.xml
Issue(s) they said they’d lobby about: Patent Reform, Medicare, Medicaid .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...